ClinicalTrials.gg
CompletedNCT06893081Updated Jul 29, 2025

A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)

A Phase 1 interventional study of MK-8527 and CBZ in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this study is to learn what happens to MK-8527 in a healthy person's body over time when MK-8527 is given alone and with the medication CBZ.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion criteria include, but are not limited to:

  • Is a healthy, adult, male or female of non- only, 18-55 years of age, inclusive
  • Is a continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior

Exclusion criteria

Exclusion Criteria:

Exclusion criteria include, but are not limited to:

  • Has a history or presence of:

    • Seizures (except for febrile seizure), or is at an increased risk for seizures
    • Family history of severe dermatologic reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome
    • hematologic diseases, bone marrow disorders, or hematologic adverse reactions to other medications
    • Depression, unusual changes in mood or behavior or suicidal thoughts or behavior
    • reaction to anticonvulsant therapy (including phenytoin, primidone, and phenobarbital)
    • Clinically significant eye disease
    • Cardiac conduction disturbance, including second-and third-degree atrioventricular heart block
  • Shown to carry or be positive for HLA-A*11:01, HLA-A*31:01, HLA-B*15:02, HLA-B*15:08, HLA-B*15:11, HLA-B*15:21, HLA-B*15:30, or HLA-B*15:31 alleles.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    MK-8527 + CBZ

    Treatment A (Period 1): Participants will receive a single dose of MK-8527 on Day 1. Treatment B (Period 2): Participants will receive CBZ twice a day on Days 1 to 20 and a single dose of MK-8527 coadministered with the morning dose of CBZ on Day 14. A washout period will separate Treatments A and B.

    Drug: MK-8527 · Drug: CBZ

Interventions

  • Oral Tablet

  • DrugCBZ

    Oral Extended-release Capsule

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from 0 to Infinity (AUC0-inf) of MK-8527

    Blood samples will be collected to determine the AUC0-inf of MK-8527 in plasma

    Time frame: Predose and at designated timepoints (up to 168 hours postdose)

  2. Area Under the Concentration-Time Curve from 0 to the Time of the Last Quantifiable Sample (AUC0-last) of MK-8527

    Blood samples will be collected to determine the AUC0-last of MK-8527 in plasma

    Time frame: Predose and at designated timepoints (up to 168 hours postdose)

  3. Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of MK-8527

    Blood samples will be collected to determine the AUC0-24 of MK-8527 in plasma

    Time frame: Predose and at designated timepoints (up to 24 hours postdose)

  4. Area Under the Concentration-Time Curve from 0 to 168 hours (AUC0-168) of MK-8527

    Blood samples will be collected to determine the AUC0-168 of MK-8527 in plasma

    Time frame: Predose and at designated timepoints (up to 168 hours postdose)

  5. Maximum Observed Plasma Concentration (Cmax) of MK-8527

    Blood samples will be collected to determine the Cmax of MK-8527 in plasma

    Time frame: Predose and at designated timepoints (up to 168 hours postdose)

  6. Time to Maximum Observed Plasma Concentration (Tmax) of MK-8527

    Blood samples will be collected to determine the Tmax of MK-8527 in plasma

    Time frame: Predose and at designated timepoints (up to 168 hours postdose)

  7. Apparent Terminal Half-Life (t1/2) of MK-8527

    Blood samples will be collected to determine the t1/2 of MK-8527 in plasma

    Time frame: Predose and at designated timepoints (up to 168 hours postdose)

  8. Apparent Clearance (CL/F) of MK-8527

    Blood samples will be collected to determine the CL/F of MK-8527 in plasma

    Time frame: Predose and at designated timepoints (up to 168 hours postdose)

  9. Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-8527

    Blood samples will be collected to determine the Vz/F of MK-8527 in plasma

    Time frame: Predose and at designated timepoints (up to 168 hours postdose)

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 60 days

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 30 days

07

Study locations

1 site
  • Celerion ( Site 0001)
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Jun 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 25, 2025
StartActual
Apr 28, 2025
Primary completionActual
Jun 19, 2025
CompletionActual
Jul 17, 2025
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06893081
Responsible party
Sponsor
First posted
Mar 25, 2025
Start date
Apr 28, 2025
Primary completion
Jun 19, 2025
Completion
Jul 17, 2025
Last update
Jul 29, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alimatravir

Start the discussion